57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial.
Saved in:
| Title: | 57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial. |
|---|---|
| Authors: | Yap, Y-S.1 (AUTHOR), Im, S-A.2 (AUTHOR), Lu, Y-S.3 (AUTHOR), Azim, H.A.4 (AUTHOR), Eralp, Y.5 (AUTHOR), Kanakasetty, G.B.6 (AUTHOR), Abdel-Razeq, H.7 (AUTHOR), Zhukova, L.8 (AUTHOR), Thuerigen, A.9 (AUTHOR), Delgar Alfaro, T.10 (AUTHOR), Wu, J.11 (AUTHOR), Gao, M.12 (AUTHOR), El Saghir, N.S.13 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1488-S1488. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.10.192 |
